Koval D. Differentiated approach to the treatment of patients with chronic obstructive pulmonary disease, depending on the level of fibrosis and inflammation markers

Object of research: chronic obstructive pulmonary disease (COPD); aim is improving principles of managing COPD patients, considering the levels of systematic inflammation markers (serum amyloid A, C-reactive protein) and fibrosis marker (TGF-beta1), improving approaches of the treatment of COPD patients, considering the severity of the disease, the severity of fibrosis and inflammation.; research methods: generally accepted clinical, laboratory, instrumental, questionnaires, functional, biochemical, immunological, statistical; novelty: the existence of a complex relationship between the markers of systemic inflammation (C-reactive protein, serum amyloid A), profibrotic cytokine (transforming growth factor-beta1 (TGF-beta1)), symptoms severity of disease and lungs ventilation function parameters, in COPD patients with a stable phase of disease; two groups of patients were allocated according to the results of the cluster analysis: one with high symptom severity, low functional indices (FEV1 ≤ 50 % of the target value), low level markers of inflammation and high systematic level TGF-beta1; another group has low symptom rates, high COPD functional indices (FEV1 ≥ 50 % of appropriate value), high levels of systematic inflammation markers and low TGF-beta1 level. Use of TGF-beta1 level, serum amyloid A and C-reactive protein as additional criteria for COPD severity was suggested. Application field – medicine.